| Cash Flow | 2025-10-31 |
|---|---|
| Net loss | -464 |
| Share-based compensation | 34 |
| Depreciation | 1 |
| Accounts receivable | -85 |
| Inventories | 96 |
| Prepaid expenses | 18 |
| Accounts payable and accrued liabilities | 117 |
| Interest on note payable | 91 |
| Net cash used in operating activities | -250 |
| Net proceeds from note payable to related parties | 350 |
| Net cash provided by financing activities | 350 |
| Net increase (decrease) in cash and cash equivalents, and restricted cash | 100 |
| Cash and cash equivalents at beginning of period | 409 |
| Cash and cash equivalents at end of period | 509 |
PURE BIOSCIENCE, INC. (PURE)
PURE BIOSCIENCE, INC. (PURE)